These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11834890)

  • 41. Differential antagonism by conotoxin rho-TIA of contractions mediated by distinct alpha1-adrenoceptor subtypes in rat vas deferens, spleen and aorta.
    Lima V; Mueller A; Kamikihara SY; Raymundi V; Alewood D; Lewis RJ; Chen Z; Minneman KP; Pupo AS
    Eur J Pharmacol; 2005 Jan; 508(1-3):183-92. PubMed ID: 15680270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of alpha1-adrenergic receptors in detrusor overactivity induced by cold stress in conscious rats.
    Chen Z; Ishizuka O; Imamura T; Aizawa N; Igawa Y; Nishizawa O; Andersson KE
    Neurourol Urodyn; 2009; 28(3):251-6. PubMed ID: 18837433
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional and radioligand binding characterization of the α1L-adrenoceptor subtype of the human vas deferens.
    Davis BJ; Wiener M; Chapple CR; Sellers DJ; Chess-Williams R
    Auton Autacoid Pharmacol; 2015 Apr; 34(3-4):41-9. PubMed ID: 25790239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Both alpha(1A)- and alpha(1B)-adrenergic receptor subtypes couple to the transient outward current (I(To)) in rat ventricular myocytes.
    Homma N; Hirasawa A; Shibata K; Hashimito K; Tsujimoto G
    Br J Pharmacol; 2000 Mar; 129(6):1113-20. PubMed ID: 10725259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypotensive effects of eugenosedin-A with serotonin, alpha- and beta-adrenoceptor antagonistic activities in spontaneously hypertensive and normotensive rats.
    Shen KP; Chiu CC; Chen SJ; Chen IJ; Wu BN
    Pharmacology; 2004 Jun; 71(2):91-101. PubMed ID: 15118348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-hypertension effect of vanylidilol: a phenylaldehyde alpha/beta-adrenoceptor blocker with endothelium-dependent and K+ channels opening-associated vasorelaxant activities.
    Chiu CC; Wu JR; Lee CH; Liou SF; Dai ZK; Chen IJ; Yeh JL
    Pharmacology; 2004 Mar; 70(3):140-51. PubMed ID: 14752234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alpha-1D adrenoceptors are involved in reserpine-induced supersensitivity of rat tail artery.
    Taki N; Tanaka T; Zhang L; Suzuki F; Israilova M; Taniguchi T; Hiraizumi-Hiraoka Y; Shinozuka K; Kunitomo M; Muramatsu I
    Br J Pharmacol; 2004 Jun; 142(4):647-56. PubMed ID: 15159276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitative imaging in live human cells reveals intracellular alpha(1)-adrenoceptor ligand-binding sites.
    Mackenzie JF; Daly CJ; Pediani JD; McGrath JC
    J Pharmacol Exp Ther; 2000 Aug; 294(2):434-43. PubMed ID: 10900216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. De novo design of a novel oxazolidinone analogue as a potent and selective alpha1A adrenergic receptor antagonist with high oral bioavailability.
    Lagu B; Tian D; Jeon Y; Li C; Wetzel JM; Nagarathnam D; Shen Q; Forray C; Chang RS; Broten TP; Ransom RW; Chan TB; O'Malley SS; Schorn TW; Rodrigues AD; Kassahun K; Pettibone DJ; Freidinger RO; Gluchowski C
    J Med Chem; 2000 Jul; 43(15):2775-8. PubMed ID: 10956183
    [No Abstract]   [Full Text] [Related]  

  • 50. Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate.
    Honda K; Nakagawa C
    J Pharmacol Exp Ther; 1986 Nov; 239(2):512-6. PubMed ID: 2877084
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
    Meyer MD; Altenbach RJ; Basha FZ; Carroll WA; Condon S; Elmore SW; Kerwin JF; Sippy KB; Tietje K; Wendt MD; Hancock AA; Brune ME; Buckner SA; Drizin I
    J Med Chem; 2000 Apr; 43(8):1586-603. PubMed ID: 10780916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic alpha 1A-adrenoceptor antagonist inhibits neointimal growth after balloon injury of rat carotid artery.
    Teeters JC; Erami C; Zhang H; Faber JE
    Am J Physiol Heart Circ Physiol; 2003 Jan; 284(1):H385-92. PubMed ID: 12388268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations.
    Martin DJ; Lluel P; Pouyet T; Rauch-Desanti C; Angel I
    Life Sci; 1998; 63(3):169-76. PubMed ID: 9698046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intraurethral pressure response to the mucosal application of neuropharmacologic agent: an experiment study.
    Tulloch AG; Rossier AB
    Urol Int; 1976; 31(3):165-70. PubMed ID: 986710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Needs and Priorities for Government Grants for Traditional Korean Medicine: Comparing the Public and Traditional Korean Medicine Doctors.
    Hyun MK
    Evid Based Complement Alternat Med; 2016; 2016():2625079. PubMed ID: 27994629
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Relationship Between Internal and External Dose: Some General Results Based on a Generic Compartmental Model.
    Slob W; Zeilmaker MJ; Hoogenveen RT
    Toxicol Sci; 2020 Sep; 177(1):60-70. PubMed ID: 32514576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Graphical Ranking of Divisors to Get the Most out of a Resolution-Enhanced Kendrick Mass Defect Plot.
    Nakamura S; Cody RB; Sato H; Fouquet T
    Anal Chem; 2019 Feb; 91(3):2004-2012. PubMed ID: 30582791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of the kinetically-derived maximum dose: Opportunities for delivering 3Rs benefits.
    Sewell F; Kimber I; Boobis AR
    Regul Toxicol Pharmacol; 2020 Oct; 116():104734. PubMed ID: 32679052
    [No Abstract]   [Full Text] [Related]  

  • 59. Continuous Intravenous Infusion.
    Farquharson EL
    Edinb Med J; 1934 Sep; 41(9):530-544. PubMed ID: 29639009
    [No Abstract]   [Full Text] [Related]  

  • 60. Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability.
    Cho HJ; Yoo TK
    Res Rep Urol; 2014; 6():113-9. PubMed ID: 25328864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.